Large Tech IPOs Stage a Comeback in a Volatile 3Q The third quarter of 2023 produced 30 IPOs that raised a combined $7.8 billion, more than the proceeds raised in the full-year 2022 despite no...read more
Eleven issuers raised a combined $939 million in July, well below the 10-year average (22 IPOs, $5.1B). Four deals raised $80 million or more, along with the year’s first direct listing (SRFM), and a wave of small issuers, which have largely disappeared...read more
Three IPOs priced this past week, led by the latest consumer success story, ODDITY Tech (ODD). DTC retailer ODDITY Tech priced above the raised range to raise $424 million at a $2.2 billion market cap. ODDITY’s current...read more
Turnstone Biologics, a Phase 1 biotech developing selected TIL therapies for solid tumors, raised $80 million by offering 6.7 million shares at $12, the low end of the range of $12 to $14. The company offered 0.9 million more shares than anticipated. Takeda had...read more
Updated: Renaissance Capital's 3Q 2023 US IPO Market Review
Large Tech IPOs Stage a Comeback in a Volatile 3Q The third quarter of 2023 produced 30 IPOs that raised a combined $7.8 billion, more than the proceeds raised in the full-year 2022 despite no...read more
Renaissance Capital's July IPO Market Update
Eleven issuers raised a combined $939 million in July, well below the 10-year average (22 IPOs, $5.1B). Four deals raised $80 million or more, along with the year’s first direct listing (SRFM), and a wave of small issuers, which have largely disappeared...read more
US IPO Weekly Recap: ODDITY jumps 50% to become the IPO market’s latest beauty queen
Three IPOs priced this past week, led by the latest consumer success story, ODDITY Tech (ODD). DTC retailer ODDITY Tech priced above the raised range to raise $424 million at a $2.2 billion market cap. ODDITY’s current...read more
Solid tumor biotech Turnstone Biologics prices IPO at $12, the low end of the range
Turnstone Biologics, a Phase 1 biotech developing selected TIL therapies for solid tumors, raised $80 million by offering 6.7 million shares at $12, the low end of the range of $12 to $14. The company offered 0.9 million more shares than anticipated. Takeda had...read more